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Introduction
Glutathione S-transferase (GST) is widely 
known as one of the principal enzymes involved in the 
metabolism of many drugs or substances in the human 
body [1]. This broad class of enzymes especially takes 
part in phase two metabolism of drugs through catalyzing 
conjugation reaction to alter drugs or substances 
into a more polar metabolite; thus, it will be easier to 
excrete [1]. GST, together with other drug-metabolizing 
enzymes, N-acetyltransferase (NAT), and cytochrome 
P450 (CYP), plays a crucial role in the metabolism of 
isoniazid (isonicotinic acid hydrazide) [2]. NAT enzyme 
takes part in isoniazid metabolism through catalyzing 
acetylation reaction, whereas CYP catalyzing oxidation 
reaction [2], [3].
GST enzyme is a soluble enzyme located 
in the cytosol, microsome, and mitochondria. GST 
enzyme in mammalian has some isoforms, including 
GSTA (alpha), GSTM (mu), GSTP (pi), and GSTT 
(theta) [4], [5]. Each isoform is encoded by a specific 
gene. Among the five isoforms of GST, GSTM1, 
and GSTT1 had been proved to involve in isoniazid 
metabolism [6]. GSTM1 enzyme is encoded by the 
GSTM1 gene located on chromosome one, while 
the GSTT1 enzyme is encoded by the GSTT1 gene 
located on chromosome 22 [6].
Some polymorphisms might potentially occur 
in such genes. The major type of polymorphism found 
in GSTM1 and GSTT1 gene is deletion [5]. Some 
evidence had shown that GST deletion contributed 
to hepatic injury induced by antituberculosis. 
However, there was a controversy regarding this 
finding in several populations [6]. Some researches 
represented a significant correlation between GST 
deletion and hepatic injury, whereas other evidence 
performed the opposite [5], [6]. Until now, there has 
been no study reporting the association between 
GST deletion and hepatic injury in the Indonesian 
population. Thus, it needs to be confirmed about this 
in our local population.
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Abstract
BACKGROUND: Glutathione S-transferase (GST), together with other drug-metabolizing enzymes 
(N-acetyltransferase and cytochrome P450), plays a crucial role in the metabolism of isoniazid (isonicotinic acid 
hydrazide). Among five isoforms of GST, GSTM1, and GSTT1 had been proved to involve in isoniazid metabolism. 
AIM: We aimed to investigate association between GST deletion and hepatic injury in the Indonesian population.
METHODS: This is a cross-sectional study. The total participants’ number was 70. Our whole blood samples were 
collected from adult pulmonary tuberculosis patients who received antituberculosis treatment category one in Bali. 
Detection for GSTM1 and GSTT1 deletion performed with the polymerase chain reaction technique using internal 
standard β-globin. Data analysis performed with the Chi-square test.
RESULTS: The proportion of GSTM1 null was 71.4% whereas the GSTT1 null was 34.3%. The proportion of 
combined GSTM1 null and GSTT1 null was 22.9%. There was no significant difference in liver damage incidence 
between GSTM1 null and wild-type (p > 0.005). There was also no significant difference in liver damage incidence 
between GSTT1 null and wild-type (p > 0.005).
CONCLUSIONS: Neither GSTM1 nor GSTT1 deletion proved to be associated with liver injury regarding 
antituberculosis use.
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Methods
Samples selection and collection
This study was an analytical observational 
study with a cross-sectional design. Our samples 
were whole blood from adult pulmonary tuberculosis 
patients who received antituberculosis treatment 
category one in Bali (which had been already collected 
on our previous research and preserved at Integrated 
Biomedical Laboratory of Medical Faculty, Udayana 
University). Inclusion criteria, including pulmonary 
tuberculosis patients in Bali, age ≥18 years old, 
received antituberculosis treatment category one and 
had already signed the informed consent. Sampling 
method using a purposive sampling technique. The 
total participants’ number was 70. Our study had been 
approved by the Ethics Committee of Medical Faculty 
Udayana University/Sanglah Hospital.
Detection of GSTM1 and GSTT1 deletion
To detect the GSTM1 and GSTT1 deletion, 
we performed the polymerase chain reaction (PCR) 
technique using internal standard β-globin. PCR was 
set on early denaturation temperature 94°C (for 5 min), 
followed by 35 cycles of denaturation (94°C for 45 s), 
annealing (55°C for 45 s), and elongation (72°C for 
45 s). Finally, the PCR temperature was ended with 
the final elongation at 72°C for five min. In the end, we 
identified the PCR product by identifying the fragment 
length for each gene: 268 bp for the β-globin gene; 
215 bp for the GSTM1 gene; and 968 bp for GSTT1 
gene. The forward and reverse primer for each gene 
was represented in Table 1.
Table 1: Forward and reverse primer for each gene
Gene Forward primer Reverse primer
β-globin 5’-GAA GAG CCA AGG ACA GGT AC-3’ 5’-CAA CTT CAT CCA CGT TCA 
CC-3’
GSTM1 5’-CTG CCC TAC TTG ATT GAT GGG-3’ 5’-CTG GAT TGT AGC AGA TCA 
TGC-3’
GSTT1 5’-CTC CCT ACT CCA GTA ACT CCC 
GAC T-3’
5’-CTG GTC ATG GTC TCT ATG 
CAA AAG A-3’
Assessment of liver injury
Hepatic injury was identified from 
the concentration of transaminase enzymes 
(including aspartate aminotransferase and alanine 
aminotransferase [ALT]) that had been assessed on 
our previous research. The transaminase level was 
measured with spectrophotometry technique. Hepatic 
injury incidence was categorized into two groups: With 
hepatic injury (at least one transaminase enzyme showed 
abnormal concentration) and without hepatic injury. 
The normal ranges of ALT and AST in the Indonesian 
population are <31 U/L and <45 U/L, respectively.
Data analysis
Our data were analyzed with statistical 
software. The comparison of hepatic injury between 
GSTM1 or GSTT1 null and wild-type was analyzed 
using the Chi-square test. p < 0.05 was considered as 
statistically significant.
Results
Subject characteristics
Of the total samples, most subjects were male 
and age above 30 years old (Table 2). Only 5.7% of 
subjects were alcoholics. There was no comorbid 
disease (including liver and kidney disease). Mostly no 
other medication taken by subjects.
Table 2: Subject characteristics
Characteristics n (%)
Sex
Male 40 (57.1)
Female 30 (42.9)
Age
<30 years old 32 (45.7)
≥30 years old 38 (54.3)
Initial AFB status
Positive 42 (60.0)
Negative 28 (40.0)
Alcohol consumption
Yes 4 (5.7)
No 66 (94.3)
Comorbid disease
Yes 0 (0.0)
No 70 (100.0)
Other medication
Yes 14 (20.0)
No 56 (80.0)
AFB: Acid fast bacil.
The Pattern of GSTM1 and GSTT1 
Genotype
The dominant genotype pattern for GSTM1 
was null-type, whereas GSTT1 was wild-type (Table 3). 
The proportion of GSTM1 null was 71.4%, whereas the 
GSTT1 null was 34.3%. The majority of our samples 
had a combination of GSTM1 null and GSTT1 wild-type. 
The proportion of combined GSTM1 null and GSTT1 
null was 22.9%.
Table 3. The pattern of GSTM1 and GSTT1 genotype
Genotype n (%)
Genotype GSTM1
Null (−) 50 (71.4)
Wild type (+) 20 (28.6)
Genotype GSTT1
Null (−) 24 (34.3)
Wild type (+) 46 (65.7)
GSTM1 and GSTT1 combination
GSTM1 (−) GSTT1 (−) 16 (22.9)
GSTM1 (−) GSTT1 (+) 34 (48.6)
GSTM1 (+) GSTT1 (−) 8 (11.4)
GSTM1 (+) GSTT1 (+) 12 (17.1)
GSTM1: Glutathione s-transferase M1; GSTT1: Glutathione s-transferase T1.
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Hepatic injury incidence in GSTM1 and 
GSTT1 deletion
As many as five subjects represented enhanced 
transaminase levels. There was no significant difference 
in liver damage incidence between GSTM1 null and 
wild-type (p > 0.05). There was also no significant 
difference in liver damage incidence between GSTT1 
null and wild type (p > 0.05). There was no significant 
difference in liver damage incidence between combined 
GSTM1 and/or GSTT1 null and GSTM1 wild-type/
GSTT1 wild-type (p > 0.05) (Table 4).
Table 4: Hepatic injury incidence according to GSTM1 and 
GSTT1 deletion
Genotype Hepatotoxic p
Yes n (%) No n (%)
GSTM1
Null 6 (12.0) 44 (88.0) 0.610
Wild type 4 (20.0) 16 (80.0)
GSTT1
Null 4 (16.7) 20 (83.3) 1.000
Wild type 6 (13.0) 40 (87.0)
GSTM1, GSTT1
GSTM1 null and/GSTT1 null 6 (10.3) 52 (89.7) 0.195
GSTM1 WT and GSTT1 WT 4 (33.3) 8 (66.7)
GSTM1: Glutathione s-transferase M1, GSTT1: Glutathione s-transferase T1, WT: Wild-type.
Discussions
For years, isoniazid has proved to be the 
primary antituberculosis drug that contributes to hepatic 
injury in tuberculosis patients. Approximately 10–20% 
of tuberculosis patients who received isoniazid will lead 
to an increase of transaminase enzyme, especially ALT, 
as many as three times the normal upper limit [2], [3].
One of the possible factor influences hepatic 
injury induced by antituberculosis is genetic variation. 
Specifically for isoniazid, genetic variations that mostly 
related to liver damage are genetic variations on the 
drug-metabolizing enzymes, including NAT2, CYP, 
GSTM1, and GSTT1 [4], [6].
GST, as the primary enzyme, plays a role in 
phase two metabolism of isoniazid, might demonstrate 
deletion, thus might result in enhanced risk of liver 
damage in tuberculosis patients who are taking 
antituberculosis. On isoniazid metabolism, GST 
enzymes detoxify the toxic metabolites of isoniazid into 
the non-toxic and excretable form [7], [8].
Our results demonstrated that the 
proportion of null-type GSTM1 was higher than wild-
type GSTM1 (71.4% vs. 28.6%). This was similar to 
evidence showed on a study in China, Japan, Thailand, 
and Turkey. The proportion of GSTM1 null in China, 
Japan, Thailand, and Turkey was 57.9%, 53.5%, 60%, 
and 72% [9]. However, some studies revealed different 
results. The proportion of null-type GSTM1 on research 
done by Teixeira et al. [10] and Santos et al. [11] in 
Brazil, and also by Gupta et al. [12] in India, was lower 
than wild-type GSTM1. The difference is highly related 
to the race variation among populations.
However, our finding revealed that there was 
no significant difference in hepatic damage incidence 
related to antituberculosis between wild-type and null-
type of GSTM1. Our result was similar to several studies 
in China, India, Brazil, and Korea [12], [13], [14], [15]. 
Some studies demonstrated contrary findings. Some 
studies stated that GSTM1 null-type increased the risk 
of hepatic injury related to antituberculosis use [16], [17]. 
Meta-analysis reports supported a significant correlation 
between GSTM1 deletion and hepatic injury in tuberculosis 
who were taking antituberculosis [8], [18], [19], [20]. 
A variation on the association of GST deletion with 
hepatic injury might particularly be influenced by a 
variation on race and ethnicity. Our finding was similar 
to other studies conducted in Asian countries, including 
India, China, and Korea. Moreover, there are also some 
other important enzymes responsible for isoniazid 
metabolism, namely, CYP and NAT2. Genetic variation 
on these genes might largely contribute to hepatic injury 
related to antituberculosis use.
Regarding our finding for the GSTT1 gene, 
the wild-type GSTT1 was the dominant genotype in 
our samples. The proportion of GSTT1 null-type in 
our research was 34.3%. This was consistent with the 
proportion of GSTT1 null-type in India (11.8%) and 
Brazil (22%) [11], [12].
There was no significant difference in liver 
damage proportion between wild-type and null-type 
of GSTT1 represented in our study. Several studies 
reported similar findings. Deletion on GSTT1 reported 
no significant association with liver damage induced 
by antituberculosis in other Asian populations, namely, 
Chinese and Indian [10], [13], [16], [21], [22], [23]. This 
supported the concept that genetic variation mostly 
influenced by race or ethnicity.
Some meta-analysis also revealed that there 
was no significant difference in hepatic injury proportion 
between GSTT1 null and wild-type in tuberculosis patients 
who were taking antituberculosis [8], [18], [19], [20]. 
In East Asian, GSTT1 was also not considered as a 
risk factor for hepatic injury related to antituberculosis 
administration [8], [18], [19], [20].
Our finding was different from evidence in 
Caucasian, India and Brazil. In the Caucasian population, 
GSTT1 deletion enhanced the risk of hepatic damage 
related to antituberculosis about 2.6 times, whereas in 
Indian, about 2.92 times [12]. Research conducted by 
Forestiero et al. [17] in Brazil reported a similar finding. 
It was revealed that GSTT1 null was significantly 
related to a mild increase of transaminase enzyme on 
tuberculosis patients who received antituberculosis. 
A report by Santos et al. in Brazil also supported this 
finding [18].
Regarding combined deletion on GSTM1 and 
GSTT1, our study found that there was no significant 
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difference in hepatic damage incidence between 
combined GSTM1 null/GSTT1 null and wild-type. Our 
result supported evidence performed by Chaterjee 
et al. [14] and Yang et al. [20]
Opposite results were stated by Gupta et al. [12] 
and Singla et al. [24]. Combined deletion on GSTM1 and 
GSTT1 gene was proved to be represented a significantly 
higher risk of hepatic damage induced by antituberculosis 
in the Indian population. The opposite result possibly 
related to the different proportion of GSTM1 deletion 
between our study and study conducted by Gupta et al. 
In our study, GSTM1 null was the dominant genotype 
for GSTM1, whereas in a study conducted by Gupta 
et al., GSTM1 wild-type was the dominant genotype for 
GSTM1 in the study population [12].
Isoniazid is a prodrug that should be converted 
first into acetyl isoniazid (catalyzed by NAT enzyme) and 
hydrazine. Hydrazine and acetyl isoniazid subsequently 
will be changed into acetyl hydrazine and finally forms 
diacetylhydrazine. Acetyl hydrazine is also metabolized 
by the CYP2E1 enzyme, forming toxic metabolite which 
then will be detoxified by GST before excreted from our 
body. Deletion on GSTM1 and GSTT1 might result in a 
decrease or loss of GST enzyme activity. This might lead 
to liver damage following the increase of isoniazid toxic 
metabolites. A variation on the association of GST deletion 
with hepatic injury might particularly be influenced by a 
variation on race and ethnicity [3], [4], [5], [6].
Conclusions
The majority of our subjects showed null-
type GSTM1 and wild-type GSTT1. Neither GSTM1 
nor GSTT1 deletion proved to be associated with liver 
injury induced by antituberculosis. Combined GSTM1 
null/GSTT1 null also revealed no significant correlation 
with hepatic damage related to antituberculosis use.
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